GlassScriptPhysician profile
Lee Cummings
NPI 1548416969
$12,269.13
in general payments reported to CMS, 2019-2025
15 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,885 · 2020: $240 · 2021: $6,000 · 2022: $130 · 2023: $97.97 · 2024: $333 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,822.71 | 2019-2021 | |
| Veloxis Pharmaceuticals, INC. | $425.47 | 2020-2025 | Envarsus |
| Dilon Technologies, INC. | $328.28 | 2024-2025 | Hemoblast Bellows |
| Sanofi-Aventis U.S. LLC | $146.48 | 2024 | |
| Paragonix Technologies, INC. | $127.48 | 2025 | Kidneyvault |
| Ipsen Biopharmaceuticals, INC | $103.62 | 2025 | Iqirvo |
| Baxter Healthcare | $97.97 | 2023 | Floseal |
| Conmed Corporation | $62.50 | 2019 | |
| Xvivo Perfusion INC. | $60.73 | 2024 | Xvivo Perfusion System (Xps) |
| Takeda Pharmaceuticals U.S.A., INC. | $25.65 | 2025 | Livtencity |
| Organox LTD | $18.42 | 2025 | |
| Apellis Pharmaceuticals, INC. | $18.00 | 2025 | Empaveli |
| Novo Nordisk INC | $16.89 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $14.93 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Cummings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.